Gland Pharma Limited IPO Message Board (Page 17)

Withdraw your application otherwise you will be in huge loss.

Greed has taken hold. Share of Rs 1 phase value offered at Rs 1500. They have left nothing on the table.What happened to UTI AMC. I think that it's listing will be on discount & atleast at 5-10% . Please apply only if you are fully confident.

Face value nothing to do with share price. Face value 1 or 100 doesn't give you any indication of whats company worth. Eg HUL face value is 1 and share value is 2100. Bankrupt companies come for 5 Paisa. It doesn't mean bankrupt companies are better than HUL.

Face value depends! Face value is always between Rs.10 and Rs.1. When the company goes for a stock split for various reasons such as more demand of shares in the market for previously issued shares or merger/demerger, the price of each share is to too much high (in that case split of shares to increase liquidity in stock) etc. In the case of gland pharma, the face value is 1 and offering price is Rs.1500 leaving no room for investors neither for the company to do future split of stocks. So it is relative if the face value is priced at Rs.10 and the price per share is Rs.1500, investors would have been optimistic. You can take the case of SBIN where the company did this to increase liquidity in the stock when its shares touched around Rs.4000 mark.

Flop show continue may be not fully subscribe retailer should avoid this IPO.

Company ads says issue closes today

First time I'm seeing retail investors avoiding ipo which is aggressively priced

Huh! Too much aggression ????

The greed of promoters and lead managers led to this situation. Retail and HNI invest hard earned money. In every IPO, atleast 10% money left for the investors. In the case of Gland pharma, the money left on the table for investors is nil. Who ever wants to invest, invest on forward multiples i.e. Future PE and EPS performance of the company

Gland Pharma IPO

GMP 21 +/- 1

GMP only at 1.5%, who will bell the cat?

What is the GMP of gland pharma ?

The way it is going... I doubt it will sail through !!!

QIB will be more than 7 times. Issue wont be cancelled. As it has already received 2920 crore out of 6480 crore issue size on end of day 2

I have 300 share of ajanta pharma
shall I tender number of shares less than 200000 rupees in order to eligible for retail category
or should I tender all my share
where are my more chances that, more number of shares are getting bought by company
1) in retail, less than 200000
2) in general and tender all 300 shares
Please help, if anyone has knowledge about it

Yes. Tomorrow is last date to buy. If you buy tomorrow it will be in your demat by friday i.e. before record date.

Why u sell or buy, just give gift to wife n son 100 shares each

Should I apply for IPO or should I buy from secondary at lower price?

Eagleye is going to apply this IPO. i am damn sure.

Railtel Corporation of India IPO – Schedule *(Tentative)*

??th Dec – Announcement of Price Band
??th Dec – Anchor Investors Allotment
??th Dec – Offer Opens
??th Dec – Offer Closes
??th Dec – Finalisation of Basis of Allotment
??th Dec – Unblocking of ASBA Accounts
??th Dec – Credit of Equity Shares to Depository Accounts
??th Dec – Commencement of Trading


Railtel Corporation of India IPO – Issue Information *(Tentative)*

Issue Opens on: ?? December 2020
Issue Closes on: ?? December 2020
Issue Type: Book Built Issue IPO
Issue Size: 8,66,53,369 Shares
Face Value: Rs.10/- per Share
Issue Price: Rs.80 – Rs.80 Share *(Tentative)*
Discount: NIL
Market Lot: 187 Shares
Listing At: NSE, BSE

Equity Shares outstanding prior to the Issue = 32,09,38,407 Shares
Employee Reservation of ??? Shares @80/- = Rs. ???.??Crs
Offer for Sale of 8,66,53,369 Shares @80/- = Rs.693.23Crs
Equity Shares outstanding after the Issue = 32,09,38,407 Shares

Category-wise Break up:
Anchor – 0 Shares = 000.00Crs
QIB – 4,33,26,683 Shares = 346.61Crs
NII – 1,29,98,006 Shares = 103.98Crs
RII – 3,03,28,680 Shares = 242.63Crs (Lot size: 187 = 1,62,185 Forms)
Empl. Quota – ???Shares = ???.??Crs
Total Issue – 8,66,53,369 Shares = 693.23Crs.

Subscription required for 1X
RII = 1,62,185 Forms
NII = 103.98Crs


Railtel Corporation of India IPO – Financial Information (Basis of Valuation)

The information is collated from the following documents:
1) DRHP = Draft Red Herring Prospectus Dated September 29, 2020 (390 pages)

EPS for FY17-18 >>> Rs.04.18 (Page #87 of DRHP)
EPS for FY18-19 >>> Rs.04.22 (Page #87 of DRHP)
EPS for FY19-20 >>> Rs.04.40 (Page #87 of DRHP)

RoNW for FY17-18 >>> 10.90% (Page #88 of DRHP)
RoNW for FY18-19 >>> 10.50% (Page #88 of DRHP)
RoNW for FY19-20 >>> 10.30% (Page #88 of DRHP)

NAV as on March 31, 2020 was Rs.42.67 (Page #88 of RHP)

Listed Industry Peer Group (Page #89 of DRHP): NONE


Railtel Corporation of India IPO – *Market’s Current Estimates of oversubscription*:

NII = 10.00K Crs. = ~96.17X
RII = 10.00L Forms = 6.17X Applic. wise (Avg allotment of ~30.33 shares per lot)

Interest cost *@7.00%p.a.* for 7days = 10.74paise for 1X

Thus, for NII the costing = 96.17 X 10.74paise = Rs.10.33 per share (= GMP)

And, for RII the costing = 30.33 X 10.33 = Rs.313/- (= Kostak)


Railtel Corporation of India IPO – *GMP Estimated*
GMP 10 +/- 1
Kostak 300 +/- 25

Plz suggest we should apply or not,
for Gland Pharma IPO

Pfizer coronavirus vaccine more than 90 per cent effective, US drug maker says
Guo said last week Fosun Pharma was hoping to be able to
sell the vaccine in China at around the same time as in Europe and the United States
. The company agreed in March to pay BioNTech a licensing fee of up to US$85 million, besides sales royalties of 35 per cent from any future annual gross profit from sales in mainland China, Hong Kong, Taiwan and Macau. It also agreed to buy US$50 million worth of BioNTech shares, which have more than tripled in value since then.
Once approved, Fosun Pharma plans to price the vaccine with a profit margin that will facilitate widespread usage on government procurement orders, while sales to the private sector will be priced based on “customer value”, Fosun Pharma’s chairman and chief executive, Wu Yifang, told an analysts conference on Tuesday.

The shares of Shanghai Fosun Pharmaceutical (Group) surged by as much as 20.8 per cent on Tuesday after the success of German partner BioNTech’s Covid-19 vaccine during clinical trials. It is hoped the company will be able to launch the shot in China after going through a bridging trial.
Praising the work done by BioNTech and Pfizer, its US partner, in markets outside China, Guo Guangchang, the billionaire chairman of majority shareholder Fosun International, said Fosun Pharma was working with regulators to speed up clinical work in China to pave the way for its sale upon approval.
“This is a victory for science, a victory for global cooperation … it is a landmark moment marking the light at the end of the tunnel in our fight against the novel coronavirus,” he wrote in his microblog. “Currently, Fosun Phama is communicating with regulators, and is striving to be able to start bridging clinical trials and to launch BNT162b2 in mainland China as soon as possible, subject to regulatory approvals,” he said.

BioNTech and Pfizer’s mRNA-based vaccine candidate BNT162b2 has proven to be more than 90 per cent effective in preventing Covid-19 infections. Photo: Reuters
BioNTech and Pfizer’s mRNA-based vaccine candidate BNT162b2 has proven to be more than 90 per cent effective in preventing Covid-19 infections, based on a global phase-three study on more than 43,500 participants that began in late July, they said in a statement late on Monday.
Fosun Pharma shares closed on Tuesday 14.2 per cent higher at HK$37.35. Fosun International, meanwhile, gained 5.4 per cent to HK$10.62.

Gland Pharma Ltd IPO: status at end of day 2
Investor Category      BSE       NSE      Total
QIB       0.31       0.16      0.47
HNI       0.02       0       0.02
Retail       0.09       0.05      0.14
Total       0.14       0.07      0.21

Abhi is ko bhul jao aur admin ko bolo naye IPOs k page khole isme time q waste kare
Reiltel dec. me aa raha hai to uske bare me q na discuss kare ?

Chinese promotors ko laga hoga... Nifty all time high ke pass hai... to apna maal bhi menghe dam me bik jayega... magar bidu eisa hou ne ko lagta nahi dikh raha....

QIB starts bidding for this IPO. Let us see what will be fate of it.

Itna sannata kyu chaya hai bhai !!!.... Aaj to 2nd day pura hone ko aaya

So gaye log. Agar price 1200 kar den to jag jayenge. Some are waiting to buy from secondary market, So will I?

Premium kya he

premium 20-24 now

https://www.scmp.com/business/article/3109192/fosun-pharma-stock-surges-prospect-covid-19-vaccine-launch-china-after
Fosun hits upper circuit, will this have a positive effect on gland?

It looks like it will nog sail through at this price. Can experts suggest fair price in case regulator extends date and bring down price.

Tomorrow morning you may see advt stating issue closes today. Issue wont be cancelled. As it has already received all fresh issue money. OFS size can always be reduced subject to meeting minimum public holding requirement which have already been achieved

AVOID
Gland pharma IPO

Reasons :
???? Chinese promotor.
???? Not fancy GMP.
???? Less possibility of listing gain .


M giving it a miss because market is at high, being cautious with sentiment Gland pharma is meant for high risk individuals for long term.

Undoubtedly it has best anchor list but less fancy GMP doesn't satisfy my appetite.

If your point of not apply is Chinese promoters then ideally shouldn't go to other factors